Sartorius Stedim Acquires Majority Stake in AllPure Technologies

Sartorius Stedim Biotech (SSB) announced that it has signed a contract to acquire the majority stake in the U.S. start-up AllPure Technologies LLC. The privately owned company based in New Oxford, Pennsylvania, USA, has been operating on the market for four years, and in 2013 earned revenue of around U.S. $3 million with 25 employees. AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Reinhard Vogt, member of SSB’s Executive Board commented: “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together.”

“We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure.

RELATED ARTICLES

A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.

A team of researchers at Michigan Technological University in collaboration with Harvard Medical School, shows how cardiomyocytes grown in a heart-like environment mature more quickly, have improved functionality and are less likely to be rejected by patients’ bodies.